// App-Quantinova.ai

: Comparative Effectiveness of Cladribine versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis The MERLYN MavEnclad Real worLd comparative efficacY non iNterventional Study

Researchers

Presenter

  • Wallace Brownlee

Principal Investigators

  • Aiden Haghikia

  • Brooke Hayward

  • Nathalie Waser

  • Sheena Kayaniyil

  • Zaeem Khan

  • Julie Duncan

  • Stephanie Millar

  • Gerard Harty

Medical Centers

  • Queen Square MS Center, UCL Institute of Neurology, London, UK

  • Department of Hematology/Oncology, Otto-von-Guericke University, Magdeburg, Germany

  • EMD Serono, Billerica, MA, USA

  • ICON plc, Burlington, Ontario, Canada

  • ICON plc, Marlow, UK

  • ICON plc, North Wales, PA, USA

  • The healthcare business of Merck KGaA

Locations

  • United Kingdom

  • Germany

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Dermatology

  • Genetic Disorder

Disease

  • Multiple Sclerosis

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

  • Fingolimod

Outcome

  • N/A

Study Design

  • Non Inferiority

  • Non Interventional

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved